The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response
Author:
Open Access
- 18 February 2014
- journal article
- review article
- Published by Springer Nature in Journal of Intensive Care
- Vol. 2 (1) , 1-11
Abstract
Pseudomonas aeruginosa is the most common gram-negative pathogen causing pneumonia in immunocompromised patients. Acute lung injury induced by bacterial exoproducts is associated with a poor outcome in P. aeruginosa pneumonia. The major pathogenic toxins among the exoproducts of P. aeruginosa and the mechanism by which they cause acute lung injury have been investigated: exoenzyme S and co-regulated toxins were found to contribute to acute lung injury. P. aeruginosa secretes these toxins through the recently defined type III secretion system (TTSS), by which gram-negative bacteria directly translocate toxins into the cytosol of target eukaryotic cells. TTSS comprises the secretion apparatus (termed the injectisome), translocators, secreted toxins, and regulatory components. In the P. aeruginosa genome, a pathogenic gene cluster, the exoenzyme S regulon, encodes genes underlying the regulation, secretion, and translocation of TTSS. Four type III secretory toxins, namely ExoS, ExoT, ExoU, and ExoY, have been identified in P. aeruginosa. ExoS is a 49-kDa form of exoenzyme S, a bifunctional toxin that exerts ADP-ribosyltransferase and GTPase-activating protein (GAP) activity to disrupt endocytosis, the actin cytoskeleton, and cell proliferation. ExoT, a 53-kDa form of exoenzyme S with 75% sequence homology to ExoS, also exerts GAP activity to interfere with cell morphology and motility. ExoY is a nucleotidal cyclase that increases the intracellular levels of cyclic adenosine and guanosine monophosphates, resulting in edema formation. ExoU, which exhibits phospholipase A2 activity activated by host cell ubiquitination after translocation, is a major pathogenic cytotoxin that causes alveolar epithelial injury and macrophage necrosis. Approximately 20% of clinical isolates also secrete ExoU, a gene encoded within an insertional pathogenic gene cluster named P. aeruginosa pathogenicity island-2. The ExoU secretory phenotype is associated with a poor clinical outcome in P. aeruginosa pneumonia. Blockade of translocation by TTSS or inhibition of the enzymatic activity of translocated toxins has the potential to decrease acute lung injury and improve clinical outcome.Keywords
This publication has 106 references indexed in Scilit:
- A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international studyBMC Infectious Diseases, 2013
- Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infectionPediatric Pulmonology, 2013
- Identification of the Major Ubiquitin-binding Domain of the Pseudomonas aeruginosa ExoU A2 PhospholipaseJournal of Biological Chemistry, 2013
- Clinical outcomes of type III Pseudomonas aeruginosa bacteremia*Critical Care Medicine, 2012
- Ubiquitin and ubiquitin‐modified proteins activate the Pseudomonas aeruginosa T3SS cytotoxin, ExoUMolecular Microbiology, 2011
- Three-Dimensional Model of Salmonella ’s Needle Complex at Subnanometer ResolutionScience, 2011
- Pseudomonas aeruginosa Cytotoxin ExoU Is Injected into Phagocytic Cells during Acute PneumoniaInfection and Immunity, 2010
- An Engineered Human Antibody Fab Fragment Specific for Pseudomonas aeruginosa PcrV Antigen Has Potent Antibacterial ActivityInfection and Immunity, 2009
- Genetic analysis of exoenzyme S expression byPseudomonas aeruginosaFEMS Microbiology Letters, 1996
- Role of exoenzyme S in chronicPseudomonas aeruginosa lung infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1985